BCL2 and cancer: In cancer cells, ITRA could suppress activated SMO and GLI, inhibiting target genes, as SOX9/mTOR, cyclin D1 (CCND1), Wnt/β-catenin, Bcl-2/cyt C, PI3K/AKT/mTOR, vascular endothelial growth factor receptor 2 (VEGFR2), multidrug resistance protein 1 (ABCC1), resulting in a block of the growth and proliferation of many cancers in vivo and in vitro, arrest of the cell cycle, inhibition of the angiogenesis, and induction of the apoptosis and autophagy [28,36].